Stock Events

AusCann 

A$0.04
10
+A$0+0% Thursday 00:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
18.06M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Nov 5
A$1
Sep 4
A$3
Sep 3
A$3
Apr 0
A$0.09
Dec 999
A$0.09
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30JunExpected
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
-0.01
-0
-0
-0
Expected EPS
0
Actual EPS
-0.0058

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AC8.AU. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Tilray Brands
TLRY
Mkt Cap1.44B
Tilray is a global leader in cannabis research, cultivation, processing, and distribution, making it a direct competitor in the medicinal cannabis market.
Canopy Growth
CGC
Mkt Cap580.69M
Canopy Growth Corporation is a world-leading diversified cannabis and cannabinoid-based consumer product company, competing in the same space as AusCann.
Cronos Group
CRON
Mkt Cap863.96M
Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents, competing with AusCann in the medicinal cannabis sector.
Aurora Cannabis
ACB
Mkt Cap332.34M
Aurora Cannabis is a Canadian licensed cannabis producer, engaged in the production and distribution of medical cannabis, directly competing with AusCann.
Curaleaf
CURLF
Mkt Cap2.15B
Curaleaf Holdings, Inc. is a leading U.S. provider of consumer products in cannabis, with a direct competition in the medicinal segment of the market.
Green Thumb Industries
GTBIF
Mkt Cap2.26B
Green Thumb Industries Inc. is a national cannabis cultivator, processor, and dispensary operator, competing in the medicinal and recreational cannabis markets, overlapping with AusCann's market.

About

AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.
Show more...
CEO
Mr. Christopher Mews A.C.I.S., ACIS, B. Bus, C.P.A., CPA
Country
AU
ISIN
AU000000AC89
WKN
000A2DLBP

Listings